Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as first-line treatment of unresectable HCC.
Unresectable Hepatocellular Carcinoma
DRUG: Adebrelimab plus Apatinib|DRUG: Adebrelimab plus Bevacizumab|DRUG: Camrelizumab plus Apatinib
12-month overall survival rate, Up to approximately 3 years
ORR, Assessed by the investigator per RECIST v1.1 criteria, Up to approximately 3 years|DCR, Assessed by the investigator per RECIST v1.1 criteria, Up to approximately 3 years|DoR, Assessed by the investigator per RECIST v1.1 criteria, Up to approximately 3 years|TTR, Assessed by the investigator per RECIST v1.1 criteria, Up to approximately 3 years|TTP, Assessed by the investigator per RECIST v1.1 criteria, Up to approximately 3 years|PFS, Assessed by the investigator per RECIST v1.1 criteria, Up to approximately 3 years|OS, Up to approximately 3 years|safety according to NCI Common Terminology Criteria for Adverse Events, version 5.0., Up to approximately 3 years
This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as first-line treatment of unresectable HCC.